Skip to main content
Premium Trial:

Request an Annual Quote

Lipomics, UCSD to Study Insulin Resistance; Lipomics to Retain Certain Dx Rights

NEW YORK (GenomeWeb News) — Lipomics Technologies and the University of California, San Diego, plan to investigate the underlying mechanisms involved in insulin-resistance disorders.
 
Under the agreement, Lipomics and UCSD will collaborate on basic and clinical research projects to study non-insulin-dependent diabetes mellitus, obesity, and other insulin-resistance disorders, as well as studies that aim to identify the roles different organ systems play in NIDDM, the company said today.
 
Lipomics said it will retain certain rights to develop diagnostic applications that will be based on information stemming from the studies.
 
Financial terms of the agreement have not been released.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.